Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.

Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk.

AIMS: To determine the relative frequency of mutations in three different genes (low-density lipoprotein receptor (LDLR), APOB, PCSK9), and to examine their effect in development of coronary heart disease (CHD) in patients with clinically defined definite familial hypercholesterolaemia in UK. PATIEN...

ver descrição completa

Detalhes bibliográficos
Main Authors:	Humphries, SE, Whittall, R, Hubbart, C, Maplebeck, S, Cooper, J, Soutar, A, Naoumova, R, Thompson, G, Seed, M, Durrington, P, Miller, J, Betteridge, D, Neil, H
Formato:	Journal article
Idioma:	English
Publicado em:	2006

Registos relacionados

The utility of DNA-based testing in patients with familial hypercholesterolaemia in the UK
Por: Humphries, SE, et al.
Publicado em: (2005)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Por: Neil, H, et al.
Publicado em: (2003)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia.
Por: Neil, H, et al.
Publicado em: (2004)

Established and emerging coronary risk factors in patients with heterozygous familial hypercholesterolaemia
Por: Neil, A, et al.
Publicado em: (2003)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study.
Por: Neil, A, et al.
Publicado em: (2008)

Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Por: Neil, A, et al.
Publicado em: (2008)

Comparison of the risk of fatal coronary heart disease in treated xanthomatous and non-xanthomatous heterozygous familial hypercholesterolaemia: a prospective registry study.
Por: Neil, H, et al.
Publicado em: (2003)

Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study.
Por: Neil, H, et al.
Publicado em: (2005)

Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic
Por: Futema, M, et al.
Publicado em: (2013)

Analysis of the frequency and spectrum of mutations recognised to cause familial hypercholesterolaemia in routine clinical practice in a UK specialist hospital lipid clinic.
Por: Futema, M, et al.
Publicado em: (2013)

The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.
Por: Scartezini, M, et al.
Publicado em: (2007)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
Por: Seed, M, et al.
Publicado em: (2009)

NOVEL INFLAMMATORY RISK MARKERS INCLUDING LPPLA2 AND RISK OF CHD IN PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH)
Por: Seed, M, et al.
Publicado em: (2009)

Development of a high-resolution melting method for mutation detection in familial hypercholesterolaemia patients.
Por: Whittall, R, et al.
Publicado em: (2010)

Statins and familial hypercholesterolaemia.
Por: Neil, A, et al.
Publicado em: (2009)

Treatment of familial hypercholesterolaemia. United Kingdom lipid clinics study of pravastatin and cholestyramine.
Por: Betteridge, D, et al.
Publicado em: (1992)

CURRENT STATIN TREATMENT OF PATIENTS WITH FAMILIAL HYPERCHOLESTEROLAEMIA (FH): RESULTS FROM THE ROYAL COLLEGE OF PHYSICIANS UK NATIONAL AUDIT
Por: Seed, M, et al.
Publicado em: (2011)

Controversies in familial hypercholesterolaemia: recommendations of the NICE Guideline Development Group for the identification and management of familial hypercholesterolaemia.
Por: Minhas, R, et al.
Publicado em: (2009)

Mortality in treated heterozygous familial hypercholesterolaemia: implications for clinical management. Scientific Steering Committee on behalf of the Simon Broome Register Group.
Por: Neil, H, et al.
Publicado em: (1999)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Por: Marks, D, et al.
Publicado em: (2000)

Screening for hypercholesterolaemia versus case finding for familial hypercholesterolaemia: a systematic review and cost-effectiveness analysis.
Por: Marks, et al.
Publicado em: (2000-01-01)

Extent of underdiagnosis of familial hypercholesterolaemia in routine practice: prospective registry study.
Por: Neil, H, et al.
Publicado em: (2000)

A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia.
Por: Marks, D, et al.
Publicado em: (2003)

Modelling a two-stage screen for autosomal dominant familial hypercholesterolaemia (FH) in UK Biobank
Por: J. Gratton, et al.
Publicado em: (2022-10-01)

DEVELOPMENT OF AN AFFORDABLE, SENSITIVE AND RAPID SCREENING METHOD FOR MUTATION DETECTION IN UK FH SUBJECTS
Por: Scartezini, M, et al.
Publicado em: (2008)

Whole exome sequencing of familial hypercholesterolaemia patients negative for LDLR/APOB/PCSK9 mutations.
Por: Futema, M, et al.
Publicado em: (2014)

Cascade screening for familial hypercholesterolaemia: implications of a pilot study for national screening programmes.
Por: Marks, D, et al.
Publicado em: (2006)

Prevalence of familial hypercholesterolaemia (FH)-causing variants and impact on LDL-C concentration in European, South Asian, and African ancestry groups of the UK Biobank
Por: J. Gratton, et al.
Publicado em: (2023-12-01)

Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia.
Por: Marks, D, et al.
Publicado em: (2002)

Cardiovascular disease morbidity is associated with social deprivation in subjects with familial hypercholesterolaemia (FH): a study comparing FH individuals in UK primary care and the UK Simon Broome register linked with secondary care records
Por: B. Iyen, et al.
Publicado em: (2022-10-01)

Effect of statin treatment for familial hypercholesterolaemia on life assurance: results of consecutive surveys in 1990 and 2002.
Por: Neil, H, et al.
Publicado em: (2004)

All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study.
Por: Neil, H, et al.
Publicado em: (2010)

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: A case-control study
Por: Talmud, P, et al.
Publicado em: (2013)

Comparing costs and benefits over a 10 year period of strategies for familial hypercholesterolaemia screening.
Por: Marks, D, et al.
Publicado em: (2003)

Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study.
Por: Talmud, P, et al.
Publicado em: (2013)

Familial hypercholesterolaemia
Por: D.J. Blom
Publicado em: (2011-01-01)

Reduction in cardiovascular disease morbidity of men and women with familial hypercholesterolaemia (FH) associated with availability of high intensity statins: A cohort study using data from the UK Simon Broome Register linked with secondary care records
Por: B. Iyen, et al.
Publicado em: (2021-09-01)

How many homozygous Familial Hypercholesterolaemia (FH) patients are there likely to be in the UK? : The FH phenotype caused by the APOB p.(Arg3527Trp) variant in a South Asian family
Por: I. Tracey, et al.
Publicado em: (2022-10-01)

Familial hypercholesterolaemia.
Por: Gill, P, et al.
Publicado em: (2012)

Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemia.
Por: Nherera, L, et al.
Publicado em: (2010)